EU CI/PS Coordinated Assessment Pilot Now Open for Applications – Single Submission for Multi-Country Medical Device Clinical Investigations
Views:60
Time:2026-11-18 13:42:56


For manufacturers planning clinical investigations or IVD performance studies across multiple EU Member States, a long-standing pain point has been clear: separate submissions to each competent authority, independent reviews, inconsistent national interpretations, duplicated documentation, heavy communication workloads and unpredictable timelines. To address these challenges, the EU has launched the CI/PS Coordinated Assessment Pilot (Pilot coordinated assessment for Clinical Investigations / Performance Studies) under Article 78 of the MDR and Article 74 of the IVDR. Sponsors only need to submit one single application to join a joint multi-country review, which substantially cuts administrative burdens for cross-border clinical programmes.This pilot also serves as a preparatory exercise for the upcoming mandatory EU coordinated assessment framework. Sponsors participating in the pilot will help the European Commission build and validate this future mandatory system, as amended by Regulation (EU) 2024/1860.



原
文
链
接


https://health.ec.europa.eu/medical-devices-clinical-investigations-and-performance-studies/pilot-coordinated-assessment-cips_en

一、Benefits for Sponsors



What advantages can sponsors gain from joining the pilot:
Single point of contact:Interact once with all participating Member States. Simplified communication chains reduce back-and-forth and the risk of approval delays.
Greater transparency and aligned regulatory practice:The assessment workflow is open, letting sponsors track progress across all reviewing authorities. National competent authorities align review practices to narrow interpretation gaps.
Streamlined RFI process:Requests for information are handled jointly. Compared with separate national assessments, repeated questions are reduced and response workload is lowered.
Consistent assessment outcomes across borders:Mitigate discrepancies in review conclusions caused by diverging national interpretations.
Reduced documentation burden:Fewer total documents are required throughout the assessment cycle.
Coordinated management of substantial modifications:Substantial changes to the study also undergo joint coordinated assessment for consistent handling.

Faster overall approval:The coordinated workflow supports competent authorities to issue national decisions more quickly.


Core Pilot Objectives:
To establish a harmonised and predictable assessment process across Member States:
  • Reduce administrative burden for sponsors
  • Improve review transparency and consistency of outcomes
  • Build practical experience for the future mandatory EU coordinated assessment system
二、Eligibility Criteria



(一)This pilot is open to sponsors running cross-border clinical investigations, subject to all the following requirements:
  1. The clinical investigation / performance study requires authorisation under Article 62(1) MDR or Article 58(1–2) IVDR.
  2. It is a multi-country study with at least two participating Member States agreeing to take part in this coordinated assessment.
  3. Device scope for MDR medical devices: Class III investigational devices, Class IIa invasive investigational devices, Class IIb invasive investigational devices.
  4. Scope for IVDR performance studies: Performance studies under Article 58(1)(a) IVDR, Article 58(1)(b)/(c) IVDR, and companion diagnostic performance studies under Article 58(2) IVDR.

Important note: Not all devices qualify. Only the above high-risk, invasive and companion diagnostic cross-border studies are eligible.

(二)Current Participating Member States:
Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Latvia, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, the Netherlands.

Each country maintains its own local implementation rules. National-specific details can be found on the official webpage.
三、Application Selection Process



The MDCG Working Group on Clinical Investigations and Evaluations reviews expressions of interest on a rolling basis. Two core evaluation criteria apply:

  • Full compliance with all eligibility requirements
  • Potential public health value of the clinical / performance study

After review, selected sponsors will receive formal notification together with a full resource package, including SOPs, guidance materials and templates. Selected sponsors have a two-week window to raise questions and arrange bilateral clarification meetings with the Secretariat and participating authorities.


Reference Documents for Submission:

  • MDCG 2021‑8
  • MDCG 2024‑3 (Clinical Investigation Plan)
  • MDCG 2024‑5 (Investigator’s Brochure)
  • Additional national-specific documentation for certain Member States
  • Summary of ethics committee opinions, official FAQ repository


Even after the coordinated assessment is completed, sponsors must complete national validation submissions in each Member State to obtain the final national authorisation.
四、Closing Remarks



The CI/PS coordinated assessment pilot represents a major EU regulatory reform to resolve duplicated reviews and inconsistent national interpretation for cross-border clinical work. It is especially relevant for Chinese manufacturers developing Class III, high-risk invasive medical devices and companion IVDs for the EU market.Should you require further support, please contact Wiselink.

Contact Us
Fill Form
Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.